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Abstract 
 
Background 
While intracranial hemorrhage (ICH) is a known complication of left ventricular 
assist device (LVAD) support, and is associated with high morbidity and mortality, 
optimal care pathways have neither been elucidated nor reported. We describe 
management of LVAD patients following ICH, with a focus on anticoagulation, 
operative interventions, care team designation, complications, and outcomes.  
Methods 
We retrospectively reviewed all durable continuous-flow LVAD implantations at our 
academic medical center from January 2007 to July 2018. Patients who 
experienced ICH after LVAD were identified. We defined baseline and ICH 
characteristics, medical and surgical interventions, care teams, and outcomes 
including death, device thrombosis, ischemic stroke, and hemorrhage expansion.   
 
Citation: Jack G. et al. (2019) 
“Managing Intracranial 
Hemorrhage in Patients with a 
Durable Continuous Flow Left 
Ventricular Assist Device.” 
The VAD Journal, 5. doi:   
https://doi.org/10.13023/VAD.201
9.08 
 
Editor-in-Chief: Maya Guglin, 
University of Kentucky 
Received: June 8, 2019 
Accepted: July 11, 2019 
Published: July 12, 2019 
© 2019 The Author(s).  This is an 
open access article published 
under the terms of the Creative 
Commons Attribution-
NonCommercial 4.0 International 
License 
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits 
unrestricted non-commercial use, 
distribution, and reproduction in 
any medium, provided that the 
original author(s) and the 
publication source are credited.   
Funding:  Not applicable 
Competing interests: Jason N. 
Katz received consultant fees 
from Abbott 
 The VAD Journal: https://doi.org/10.13023/vad.2019.08 Page 2 of 13 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Results 
A total of 321 patients underwent LVAD implantation during the study period, and 
27 (8%) developed ICH (17 intraparenchymal, 7 subdural, 2 subarachnoid, 1 
intraventricular) while on support. Twenty-five were anticoagulated at onset of 
bleed. Of those, 13 were managed with immediate cessation of anticoagulation 
and administration of reversal products (Group A). Group A had a median of 6 
days off anticoagulation and 60 days of follow up with 1 patient (8%) developing 
device thrombosis at day 8, 1 (8%) developing subsequent ischemic stroke at day 
14, and 4 (31%) with ICH expansion. Seven patients had anticoagulation stopped 
at onset of bleed without administration of reversal products (Group B). With a 
median of 2 days off anticoagulation and 2 days of follow up, no patients in Group 
B developed ischemic stroke or device thrombosis while 1 (14%) had ICH 
expansion. Five patients had anticoagulation continued at onset of bleed (Group 
C) with a median follow up of 330 days. One (20%) developed device thrombosis 
at day 5 while 2 (40%) developed ICH expansion. Four patients with subdural 
hemorrhage underwent Burr hole drainage with all 4 surviving to discharge. Two 
patients with intraparenchymal hemorrhage underwent open craniotomy with 
neither surviving to discharge. An interdisciplinary discussion occurred in all cases. 
Following ICH, only one-third of patients in the study survived to 6 months.  
Conclusion 
LVAD patients who experience an ICH have variable outcomes. Their care is 
multidisciplinary and can involve operative intervention. The discontinuation and 
reversal of anticoagulation is generally well-tolerated, with a low risk for early 
device thrombosis. Like for many hemorrhagic complications of LVADs, ICH often 
persists or worsens. Additional investigation is needed to elucidate the most 
optimal management strategies.  
Keywords: LVAD, intracranial hemorrhage, anticoagulation 
 
Introduction  
Though chronic heart failure is associated with substantial morbidity and mortality, 
the use of contemporary left ventricular assist devices (LVADs) has resulted in 
significant improvements among eligible patients (1-4). With that being said, there 
is still risk associated with device use. One well-recognized complication is that of 
bleeding, tied at least in part to the need for systemic anticoagulation. One 
potentially devastating bleeding event is that of intracranial hemorrhage (ICH). 
Those who develop ICH on LVAD support have markedly worse survival, and 
hemorrhagic strokes carry a considerably greater liability for LVAD patients than 
ischemic events (5, 6). 
Although studies have identified risk factors associated with the development of 
ICH in LVAD patients, the actual management of this complication has been 
largely overlooked (7, 8). Treatment practices have been infrequently described 
and have been limited to small observational reports, and there are currently no 
guidelines for the management of ICH in this patient population. Additionally, the 
INTERMACS database, which collects clinical data including bleeding 
complications for LVAD patients, notably excludes details on the management of 
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ICH (9). For these reasons, treatment of ICH complicating LVAD use has been 
largely institution-dependent and driven by clinician experience and preference.  
The current study was conducted in order to describe the management of LVAD 
patients following ICH, with a particular focus on anticoagulation, operative 
intervention, resource utilization, care team dynamics, complications, and clinical 
outcomes.  
Methods 
This study was reviewed and approved by the University of North Carolina (UNC) 
Institutional Review Board. Patients who received a continuous-flow, durable 
LVAD were identified using the UNC Mechanical Heart Program VAD tracking 
sheet which includes all patients at our institution who have received an 
intracorporeal mechanical circulatory support device since January 2007. We 
performed a thorough medical record review of those patients who underwent 
placement of a Jarvik 2000 (Jarvik Heart, Inc., New York, NY), HeartMate II 
(Thoratec, Pleasanton, CA), HeartMate III (Abbott, Chicago, IL) or HVAD 
(Medtronic, Dublin, Ireland) from January 2007 to July 2018 in order to identify 
those who had developed ICH following device implantation. 
Data that were systematically abstracted from the electronic medical record 
included patient demographics (age, gender, and race) LVAD type, ICH type (IPH, 
intraparenchymal hemorrhage; SDH, subdural hemorrhage; SAH, subarachnoid 
hemorrhage; or IVH, intraventricular hemorrhage), days post-LVAD implantation, 
setting at ICH onset, mechanism of ICH, medical decision-making strategies 
(including management of antiplatelet and anticoagulation regimens, operative 
management including placement of Burr hole or open craniotomy), complications 
(including device thrombosis, ischemic stroke, and worsening bleed), resource 
consumption (including specialty care consultation and hospital unit placement), 
and mortality. Size of ICH was also calculated for IPH only (using the formula ABC 
divided by 2 where A = max height, B = max length, C = max depth). Location of 
bleed was collected for IPH and SAH (i.e. frontal, parietal, temporal, occipital, 
basal ganglia, or brainstem).  
Those patients who were anticoagulated at the time of bleed were divided into 
three groups based on their anticoagulation management strategy: those who had 
anticoagulation immediately held with administration of reversal products (Group 
A), those who had anticoagulation immediately held without administration of 
reversal products (Group B), and those who had anticoagulation continued (Group 
C). Complication rates and survival outcomes were calculated for these three 
groups and stratified by type of hemorrhage.  
Results  
Study Population   
From January 2007 to July 2018, 321 patients at our institution underwent 
placement of a durable, continuous-flow, intracorporeal LVAD, with 27 (8%) 
subsequently developing ICH while on mechanical support. The median time 
between LVAD implantation and ICH was 187 days (range = 4 – 1739 days). 
Among those who developed ICH, the average age at time of bleed was 63.1 
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years with the vast majority of patients being Caucasian or African American 
males with a HeartMate II (Table 1).  
   Table 1 – Patient characteristics, Clinical Data, and Management 
N Age, 
Sex, 
Race 
LVAD Presenting 
Symptom 
ICH 
Type 
ICH 
Size 
(cm3) 
INR ICH 
Location 
Days 
post-
implant 
Set- 
ting 
Mech- 
anism 
Anticoagulation 
Management  
Surgery 
 
Survival 
 
1 58  
WF 
HMII      Altered  
     Mental  
     status 
    
IPH 91 ADL L 
temporal 
158 OH Sponta- 
neous 
Warfarin held without 
reversal 
None <1 day 
2 37 
WM 
Jarvik Altered 
Mental 
Status 
IPH 106 1.3 R frontal 75 IH Sponta-
neous 
Heparin stopped without 
reversal  
None 2 days 
3 51  
BM 
HMII Headache SAH N/A 3.3 R frontal 123 IH Sponta-
neous 
Warfarin continued given 
history of APLA, 
DVT/PE, and LVAD 
thrombosis; switched to 
heparin day 4; warfarin 
restarted day 40 and 
heparin stopped 5 days 
after 
None > 6 
months 
4 74 
WM 
HMII Headache SDH N/A 1.8 Right 266 OH Traumatic Warfarin held; given 
Vitamin K;  warfarin 
restarted on day 30 
None > 6 
months 
5 64  
BF 
HVA
D 
Confusion IPH 14 2.0 L 
temporal 
105 IH Traumatic Warfarin plus heparin 
bridge stopped; given 
FFP and Vitamin K; 
warfarin restarted on day 
4 
None > 6 
months 
6 62 
WM 
HMIII Altered 
Mental 
Status 
SAH N/A 1.8 R parietal 143 IH Sponta-
neous 
Heparin stopped; given 
protamine; warfarin and 
heparin bridge restarted 
on day 6 
None 2 months 
7 69 
WM 
HMII Unrespons
iveness 
SDH N/A 1.4 Right 198 OH Traumatic Warfarin held; given 
Factor 7 
Cranio-
tomy 
< 1 day 
8 68 
WM 
HMII Unknown SDH N/A 1.4 L 
tentorium 
329 IH Traumatic Not on anticoagulation 
given GI bleed 2 weeks 
prior; anticoagulation not 
restarted 
None 49 days 
9 58 
NAF 
HVA
D 
Unrespons
iveness 
IPH unkn
own 
4.3 R fronto-
parietal 
86 IH Sponta-
neous 
Warfarin held; given 
PCC, Vitamin K, and 
FFP 
None 2 days 
10 45  
BM 
HMII Altered 
mental 
status, 
drowsi-
ness 
IPH 108 1.4 R 
occipito-
parietal 
122 IH Sponta-
neous 
Heparin stopped; given 
protamine 
None < 1 day 
11 65 
BM 
HMII Headache, 
Nausea, 
vomiting 
SDH N/A 1.0 Bilateral 548 OH Traumatic Not on anticoagulation 
given GI bleed 2 weeks 
prior; warfarin restarted 
30 days after ICH 
Burr 
Hole 
Drain 
> 6 
months 
12 69 
WF 
HMII Nausea, 
Headache 
IPH 105 2.9 L 
occipito-
temporo-
parietal 
846 IH Sponta-
neous 
Warfarin held without 
reversal 
None < 1 day 
13 67  
BM 
HMII Headache IPH 27 5.1 R 
occipital 
374 OH Sponta-
neous 
Warfarin held; given 
FFP, PCC, Vitamin K, 
Factor 9, and Factor 2; 
None 77 days 
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warfarin restarted day 28 
14 79  
BM 
HMII Headache, 
left arm 
symptoms 
SDH N/A 3.3 Right 701 OH Sponta-
neous 
Warfarin held; given 
PCC and Vitamin K; 
warfarin restarted 64 
days later 
Burr 
Hole 
Drain 
> 6 
months 
15 71 
WM 
HMII Unknown IPH < 1 1.2 L frontal 4 OH Hemorr-
hagic 
Conver- 
sion 
Heparin continued Un-
known 
26 days 
16 58 
WM 
HMII Lethargy IPH 26 1.59 L fronto-
temporal 
26 IH Hemorr-
hagic 
Conver- 
sion 
Warfarin continued; 
heparin added as bridge 
for subtherapeutic INR 
None 6 days 
17 56 
WM 
Jarvik Left-sided 
weakness 
IPH 133 1.10 R fronto-
parietal 
616 IH Sponta-
neous 
Warfarin held; given 
PCC and Vitamin K 
None 2 days 
18 72 
WM 
HMII Incidental 
finding 
SDH N/A 2.3 Right 175 OH Traumatic Warfarin held without 
reversal and restarted on 
day 31 
None 4 months 
19 84 
WM 
HMII Slurred 
Speech 
IPH 16 3.58 L frontal 1739 OH Hemorr-
hagic 
Conver- 
sion 
Warfarin held without 
reversal 
None < 1 day 
20 43 
BF 
HMII Slurred 
Speech 
IPH < 1 1.92 L frontal 160 OH Hemorr-
hagic 
Conver- 
sion 
Warfarin continued None > 6 
months 
21 48  
BM 
HMII Headache SDH N/A 3.51 Right 945 OH Traumatic Warfarin replaced with 
lovenox; warfarin 
restarted on day 3 
Burr 
Hole 
Drain 
> 6 
months 
22 55  
BM 
HMII Headache, 
right 
hemipare-
sis 
IPH 10.8 1.7 L parietal 1220 IH Sponta-
neous 
Heparin stopped; given 
FFP and Vitamin K; 
warfarin started on day 
33 
None > 6 
months 
23 77  
BM 
HMII Lethargy, 
right 
hemipares
is 
IPH 114.9
5 
1.16 L frontal 99 OH Sponta-
neous 
Warfarin held; given 
PCC and Vitamin K 
Cranio-
tomy 
6 days 
24 77  
BM 
HMII Confusion 
Nausea 
IVH N/A 4.47 Right 3rd 
ventricle 
1632 OH Sponta-
neous 
Warfarin held; given 
PCC and Vitamin K; 
prophylactic heparin (x) 
day 3; ACS nomogram 
heparin(y) day 21; 
warfarin restarted day 47 
Burr 
Hole 
Drain 
> 6 
months 
25 64 
WM 
HMII Left 
hemipares
is 
IPH 0.91 1.2 R basal 
ganglia 
65 IH Hemorr-
hagic 
Conver- 
sion 
Warfarin held without 
reversal, heparin drip on 
day 9 
None 10 days 
26 82 
WM 
HMIII Altered 
Mental 
Status, 
Drowsi-
ness 
IPH 14.5 1.75 L 
occipital 
29 IH Hemorr-
hagic 
Conver- 
sion 
Warfarin and heparin 
both held without 
reversal 
None 2 days 
27 63  
BF 
HMII Inattentive
-ness, 
confusion 
IPH 32 2.48 L frontal 149 OH Sponta-
neous 
Warfarin held; given FFP 
and Vitamin K; heparin 
drip started day 8 for 
LVAD thrombosis 
None 8 days 
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ADL = above detectable limit; BF=black female, BM=black male; HMII=HeartMate II; HMIII= 
HeartMate III; IH= in hospital; IPH=intraparenchymal hemorrhage; NAF= Native American 
Female; OH=out of hospital; PCC = prothrombin complex concentrate; SDH= subdural hematoma; 
WF=white female; WM=white male 
(x) 5000 units unfractionated heparin every 8 hours  (y) unfractionated heparin infusion titrated to goal 
heparin correlation of 0.3 – 0.5. 
 
ICH Characteristics 
Among the 27 cases of ICH, there were 17 intraparenchymal, 7 subdural, 2 
subarachnoid, and 1 intraventricular event. Of the 17 patients who developed IPH, 
10 presented with spontaneous hemorrhage, 6 with hemorrhagic conversion of an 
ischemic stroke, and 1 with head trauma. Of the 7 patients who suffered SDH, 6 
had a history of head trauma or fall while 1 had no history of either. Of the 2 
patients who developed SAH and 1 with IVH, none had a history of recent head 
trauma, fall, or ischemic stroke. Thirteen patients developed an ICH while 
inpatient, and of these 4 had been hospitalized for LVAD implantation, 4 were 
being treated for bacteremia or LVAD pocket infection, 2 for ischemic stroke, 1 for 
CHF exacerbation, 1 for pre-operative anti-coagulation management, and 1 for 
suspected LVAD thrombosis.  Fourteen patients developed bleeding outside of the 
hospital (Table 1).  
Anti-thrombotic Management & Complications 
Twenty-one patients (78%) were on antiplatelet therapy at presentation with 19 
(70%) on aspirin alone, one (4%) on prasugrel alone, and one (4%) on a 
combination of aspirin and clopidegrel. Only 4 patients had antiplatelet therapy 
continued at the time of bleed, all of whom were being treated for hemorrhagic 
conversion of an ischemic stroke. Three patients had antiplatelet therapy restarted 
at 1 week, 1 month, and 2 months respectively.  
Twenty-five patients (93%) were anticoagulated at presentation with 19 (70%) on 
warfarin, 2 (7%) on a heparin infusion, and 4 (15%) on warfarin plus a heparin 
infusion. INR at time of presentation ranged from 1.1 to above the detectable limit. 
Due to recent history of GI bleeding, 2 patients (7%) were not anticoagulated at 
the time of their ICH. Among the 25 patients who were anticoagulated, 13 were 
managed with immediate cessation of anticoagulation and administration of 
reversal products (Group A), 7 were managed with immediate cessation of 
anticoagulation without administration of reversal products (Group B), and 5 were 
managed with continuation of anticoagulation (Group C). In Group A, reversal 
products utilized included Fresh Frozen Plasma (FFP), Prothrombin Complex 
Concentrate (PCC), vitamin K, and protamine. In Group B, many different clinical 
factors contributed to the decision to withhold reversal products. Specifically, 4 
patients presented with unrecoverable bleeds and were managed with comfort 
measures only, 1 patient had an asymptomatic SDH for which reversal was 
deemed unnecessary, 1 patient had an ischemic stroke with a very small ICH from 
hemorrhagic conversion, and 1 patient had signs of chronic subclinical LVAD 
thrombosis. Given the poor prognosis of this group in general, their follow-up time 
was very limited. In Group C, anticoagulation was continued for several reasons. 
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Three patients had an ischemic or embolic stroke with two of the three having less 
than 1 cm3 volume ICH, 1 patient had a SDH with intact neurologic status, and 1 
patient had a history of antiphospholipid antibody syndrome complicated by prior 
LVAD thrombosis. In these 5 cases it was thought that the risk of discontinuing 
anticoagulation outweighed the benefits. 
With a median follow-up of 26 days (range = 1 – 1350 days) in these 25 patients 
with ICH while on anticoagulation, there were a total of 2 patients with subsequent 
device thrombosis and 1 patient with ischemic stroke over the course of the study 
– none of which occurred within the first week after bleed. Group A had a median 
of 6 days off anticoagulation and 60 days median follow-up time with only 1 (8%) 
patient developing device thrombosis at day 8. One (8%) patient in this group 
developed ischemic stroke at day 14. Four (31%) had evidence of worsening 
bleeding which all occurred within 1 week (Figure 1). Group B had a median of 2 
days off anticoagulation and 2 days of follow up time with no episodes of device 
thrombosis or ischemic stroke. One (14%) patient had evidence of worsening 
bleeding on day 1. Group C had a median follow-up time of 330 days with 1 (20%) 
device thrombosis at day 5 in a patient with a history of antiphospholipid antibody 
syndrome and multiple LVAD thromboses in the past. Expansion of ICH occurred 
in 1 (20%) patient on day 27 (Table 2).  
Care Team Designation & Surgical Intervention  
In all cases, an interdisciplinary discussion took place between cardiology, 
neurosurgery, neurology, cardiac surgery, and/or hematology. Eight (30%) patients 
had at least one consultant note that weighed the risk of device thrombosis heavily 
in clinical decision-making. Eighteen (67%) patients were treated in the cardiac 
intensive care unit (ICU), 2 (7%) in the neurosurgical ICU, and 6 (22%) in the 
cardiac intermediate unit (Table 3). One patient was taken to the operating room 
and died before being assigned to a hospital unit. Glasgow Coma Scale (GCS) 
was recorded only in 12 (44%) patients. NIH Stroke Scale (NIHSS) was recorded 
for 8 patients (30%) and Glasgow Outcome Scale (GOS) was not recorded for any 
patients.  
Table 2: LVAD Thrombosis, Ischemic Stroke, Worsening Bleed, and Death Stratified 
by Anticoagulation Strategy 
 Anticoagulation Management 
 Group A Group B Group C 
 Reversed Held Continued 
No. of patients 13 7 5 
Follow up time (days), 
median 
60 2 330 
Days off AC, median(a) 6 2 - 
Days off AC, range(a) 1 - 65 1 - 31 - 
Device Thrombosis  1 (8) 0 (0) 1 (20) 
Ischemic Stroke 1 (8) 0 (0) 0 (0) 
Expansion of ICH (b) 4 (31) 1 (14) 1 (20) 
Death at 24 hours (%) 2 (15) 3 (43) 0 (0) 
Death at 30 days (%) 6 (46) 6 (86) 2 (40) 
Death at 6 months (%)  8 (62) 7 (100) 2 (40) 
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(a) Ended with either resumption of anticoagulation or death 
(b) defined as clinical or radiographic evidence of hemorrhage expansion 
AC = Anticoagulation 
ICH= Intracranial hemorrhage 
 
Table 3: Care Team and Hospital Unit 
No. of Patients, total (a) 27 
Primary Team (%)  
Cardiology 21 (78) 
Cardiac Surgery 2 (7) 
Neurosurgery 3 (11) 
Consultants (%) (b)  
Neurosurgery 20 (74) 
Neurology 14 (52) 
Cardiology 5 (19) 
Hematology 
Hospital unit (a)(%) 
2 (7) 
CICU 18 (67) 
NSICU 2 (7) 
Cardiac Intermediate 
Care           
6 (22) 
_________________________________________________ 
(a) One patient was taken to the OR and died before being assigned to a unit and before 
consult teams could be assigned 
 
Surgical intervention was performed in a total of 6 patients. This included 4 
patients with SDH who underwent Burr hole drainage and 2 patients with IPH who 
underwent open craniotomy.  
Outcomes 
Survival outcomes varied by management group (A, B, and C) and by ICH subtype 
(Table 2 and 4, respectively). Thirty-day mortality was 46%, 86%, and 40% in 
Groups A, B, and C respectively, while 6-month mortality was 62%, 100%, and 
40% respectively. Patients who presented with IPH had the worst outcomes with a 
76% rate of death at 30 days compared to only 14%, 0%, and 0% in patients with 
SDH, SAH, and IVH respectively. Both patients who underwent open craniotomy 
for IPH died within 6 days. On the other hand, all four patients who underwent Burr 
hole drainage survived to 6 months.  
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Table 4: Survival Outcomes  
 IPH SDH SAH IVH All 
      
Death at 24 hours (%) 4 (24) 1 (14) 0 (0) 0 (0) 5 (19) 
Death at 30 days (%) 13 (76) 1 (14) 0 (0) 0 (0) 14 (52) 
Death at 6 months (%)  14 (82) 3 (42) 1 (50) 0 (0) 18 (72) 
      
IPH= intraparenchymal hemorrhage; IVH= intraventricular hemorrhage; SAH= 
subarachnoid hemorrhage; SDH=subdural hemorrhage   
Discussion 
In this case series assessing anticoagulation management, surgical intervention, 
care team utilization, complications, and outcomes among continuous-flow LVAD 
patients presenting with ICH, we found that the majority of patients were middle-
aged males with a Heartmate II device, almost all of whom were anticoagulated at 
presentation. The etiology of ICH included traumatic, spontaneous, and 
hemorrhagic conversion with about half of patients developing ICH while already in 
the hospital for an alternative reason. Clinical management strategies varied 
across our patient population with mixed outcomes. Most notably, cessation of 
anticoagulation with administration of reversal products was generally well 
tolerated in the short term, with no episodes of device thrombosis or ischemic 
stroke occurring within the first week when this strategy was employed. On the 
other hand, about one-quarter of patients in the study had clinical or radiographic 
evidence of worsening bleeding; the majority of which did occur within the first 
week. Intracranial hemorrhage was associated with poor outcomes as only one-
third of patients in the study survived to 6 months.  
While the management of anticoagulation in the LVAD patient with ICH remains a 
unique and challenging dilemma, the data currently available to guide treatment 
remains limited. In a single-center study of LVAD patients presenting with ICH, 
Wilson et al followed 22 individuals who had warfarin held and reversed for a 
median of 10.5 days and found that none developed device thrombosis or stroke 
(10). This study, however, was performed largely among patients supported with a 
pulsatile LVAD rather than a contemporary continuous-flow device. A similar study 
by Wong et al analyzed the efficacy of vitamin K antagonist reversal using 4-factor 
PCC versus traditional reversal strategies in continuous flow devices and found 
only one LVAD thrombosis and no ischemic strokes among 20 cases (11). This 
study was also limited by the fact that the average time off anticoagulation was not 
reported, making it difficult to interpret and generalize. In the largest observational 
study to date, Tahir et al found that ICH size, midline shift, and GCS score were 
predictive of mortality, but they did not report data on reversal strategies or rates of 
device thrombosis (12). Our study revealed no device thrombosis or ischemic 
stroke within the first week in patients managed with swift cessation and reversal 
of anticoagulation. However, almost one-third of patients had consult notes which 
weighed the risk of device thrombosis and ischemic stroke heavily in clinical 
decision-making. Additionally, a significant proportion of patients across all 
treatment groups demonstrated clinical or radiographic evidence of worsening 
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bleeding within the first week. One could therefore make a compelling argument 
that in the short term, the risk of bleeding may outweigh the risk of clotting in such 
cases. With the fully magnetically-levitated HeartMate 3 demonstrating lower rates 
of ischemic stroke and pump thrombosis but similar rates of bleeding compared to 
the older HeartMate 2, we expect this pattern may persist (13, 14).   
 
The role of neurosurgical intervention in this patient population remains even more 
unclear. Although small studies suggest non-cardiac surgery in the LVAD patient 
does not significantly increase morbidity and mortality, very few specifically assess 
outcomes after intracranial hematoma evacuation (15-17). In a recent study by 
Ikeda et al, 6 of 7 LVAD patients with ICH who underwent acute operative 
intervention (6 craniotomies and 1 burr hole drainage) died within 30 days (18). 
Wilson et al reported similar results, with four of five patients who underwent 
craniotomy dying within 60 days (10). At our institution, both patients treated with 
open craniotomy died within 1 week while all 4 patients who underwent Burr hole 
drainage for subdural hematoma survived to 6 months. Other studies have also 
shown Burr hole drainage to be generally well tolerated in these cases (10). 
Whether the poor outcomes seen with craniotomy are due to sicker patients going 
to the OR is unclear, and more data is needed to make definitive 
recommendations. Notably, the 2015 American Heart Association/American Stroke 
Association guidelines on the management of spontaneous intracranial 
hemorrhage state that, in general, the role of surgery for supratentorial ICH is not 
well established (19).  
 
Our study is the first to describe care team designation and hospital unit admission 
patterns as key factors that may impact patient management. The majority of 
patients were treated in either a cardiac ICU or a cardiac intermediate care unit 
with cardiac intensivists or cardiac surgeons serving as leaders of the care team. 
Two patients were managed in the neurosurgical ICU. With very few exceptions, 
all patients were also followed by a neurosurgery and/or neurology consultant 
team. Whether to manage these patients in the cardiac versus neurosurgical ICU 
remains controversial, with clinical resources and specialized nurse training 
playing a key role in this debate. The cardiac ICU allows for closer and more 
experienced monitoring of potential LVAD dysfunction such as device thrombosis, 
arrhythmia, and heart failure, whereas the neurosurgical ICU may allow for more 
optimal management of ICH including monitoring of intracranial pressures, tracking 
of cerebral perfusion pressures, early identification of dynamic changes in 
neurologic function, and other tasks that may benefit from more specialized 
nursing care (20). As an example, we found that less than half of our patients who 
were treated in a cardiac unit had either Glasgow Coma Scale (GCS) or NIH 
Stroke Scale (NIHSS) recorded during their hospital stay, and none of the patients 
had a Glasgow Outcome Scale documented. Given that GCS and other stroke 
assessment scores have been shown to be important in the management of ICH, 
and that the AHA/ASA recommends that nurses caring for these patients be 
trained in obtaining these scores, this study highlights the need to more closely 
examine these care practices in our cardiac-specific ICUs (19). Given the low risk 
of early device thrombosis in our patient population, the potential for rapid 
neurologic decline, and the level of specialized care needed to treat an acute 
intracranial bleed, one might consider treating LVAD patients with ICH in a 
neurosurgical ICU or dedicated stroke unit rather than the cardiac ICU. The risks 
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and benefits of this approach should currently be evaluated on a case-by-case 
basis, but we believe this strategy could and should be more rigorously assessed 
in a prospective clinical study.  
 
In addition to prospective clinical assessment, we suggest that more data 
elements concerning ICH be collected as part of the INTERMACS database. This 
should include ICH subtypes, management practices (including pharmacologic 
reversal agent use and operative interventions), and neuro-specific outcomes. 
More data is certainly needed to understand which components of management 
truly influence patient outcomes. 
 
Our study utilized rigorous chart review to gather clinical data not previously 
reported in larger studies, and is the first to collect data on care team designation 
and hospital unit following ICH. There are, however, several limitations that should 
be considered. First, given the small sample size our results should be viewed as 
largely descriptive. We did not have the necessary power to make direct statistical 
comparisons across groups. Instead we focused on providing rigorous data related 
to care processes and stroke characteristics that we hope will serve as a basis for 
future investigation. Second, the majority of patients in Group B suffered 
devastating bleeds, were transitioned to comfort measures within 1 or 2 days of 
admission, and died shortly thereafter, thus limiting their follow up time. Finally, as 
previously mentioned, our records did not consistently include data relevant to 
stroke outcomes such as GCS, NIHSS, GOS, and Rankin scale.   
 
Conclusion 
 
Patients with LVADs who experience an ICH have very high mortality rates. Their 
care is multidisciplinary and can involve operative intervention in certain 
circumstances. Early reversal of anticoagulation is generally well tolerated with a 
low risk of early device thrombosis or ischemic stroke. Like for many hemorrhagic 
complications of LVADs, bleeding after ICH often persists or worsens. Additional 
prospective studies are needed to provide future guidance to clinicians faced with 
this difficult, and often devastating clinical event. 
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